⌕
Abbvie · ABBV · NYSE
Tenet 42 · Weak
Compare
$295.03+0.20%At closeTenet 42 · Weak
$295.03+0.58 (+0.20%)
At close: Nov 13, 2026, 4:00 PM ET· NYSE · USD
$294.51
After hours: Nov 16, 2026, 5:50 PM ET

Abbvie (ABBV) Stock

Abbvie (ABBV) closed at $295.03 on Nov 13, 2026; its Tenet Score is 42 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

14 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$295.03
Nov 13, 2026
Market cap
$521.5B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
50.6×
price ÷ earnings
Dividend yield
2.35%
past year's regular dividends ÷ price
52-week range
190.75 – 302.93
low → high · as of close, Nov 13, 2026
Tenet Score
42/100
Weak · 313 Healthcare peers

Industry: Drugs

Abbvie Inc scores 42/100. Weak. Strongest on quality, financial health is the soft spot, trading at 51× earnings versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
42/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
39
Quality
70
Health
14
Growth
46

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueDQualityBHealthFGrowthDMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
7.9×
price to fiscal 2025 sales
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
24.6%
fiscal 2025, before interest and tax
Net margin
15.7%
of revenue kept
Current ratio
0.87
current assets to liabilities
Net debt / EBITDA
2.4×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Abbvie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasi…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 523 US ETFs · top wrappers by weightSee all ETFs holding ABBV →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

CompanyTenet ScoreMarket cap
Lilly(Eli) & CoLLY49$1.29T
Johnson & JohnsonJNJ48$687.9B
Merck & Co IncMRK41$364.3B
Novartis AGNVS56$306.3B
AMGEN Inc.AMGN47$251.9B
Gilead Sciences, Inc.GILD37$208.5B
Novo NordiskNVO63$185.9B
Pfizer Inc.PFE50$164.7B
Vertex Pharmaceuticals, Inc.VRTX55$136.6B
Bristol-Myers Squibb Co.BMY51$129.7B

Compare Abbvie with

What sector and industry is Abbvie in?

Abbvie is in the Healthcare sector and the Drugs industry.

What is Abbvie's Tenet Score?

Abbvie's Tenet Score is 42 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.